b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">\n        <PMID Version="1">30785209</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>06</Month>\n            <Day>12</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>06</Month>\n            <Day>13</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Print">1121-7138</ISSN>\n                <JournalIssue CitedMedium="Print">\n                    <Volume>42</Volume>\n                    <Issue>2</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Apr</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>The new microbiologica</Title>\n                <ISOAbbreviation>New Microbiol.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Italian expert panel consensus statements on two-drug antiretroviral regimens to treat na\xc3\xafve and virologically suppressed HIV-1 infected patients.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>69-80</MedlinePgn>\n            </Pagination>\n            <Abstract>\n                <AbstractText>New strategies for HIV treatment able to reduce drug-exposure, medium-long term toxicities and costs are a recognized clinical need. The availability of newer drugs with improved potency and tolerability, as well as high genetic barrier to resistance, makes antiretroviral-sparing strategies with two-drug regimens (2DRs) particularly attractive. Substantial evidence has been generated over the last few years supporting 2DR in virologically suppressed HIV infected patients for whom a therapy switch is planned. More recently, very promising data on 2DR in na\xc3\xafve patients have also been reported. The main purpose of this consensus is to provide an overview of guideline indications and recommendations, and the most recent data from clinical studies of 2DR in both na\xc3\xafve and virologically suppressed patients. As an expert consensus, suggestions and indications on the use and management of 2DR are also provided.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Antinori</LastName>\n                    <ForeName>Andrea</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Santoro</LastName>\n                    <ForeName>Maria Mercedes</ForeName>\n                    <Initials>MM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Experimental Medicine, University of Rome &quot;Tor Vergata&quot;, Rome, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Gagliardini</LastName>\n                    <ForeName>Roberta</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Marchetti</LastName>\n                    <ForeName>Giulia</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, Presidio San Paolo, University of Milan, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mondi</LastName>\n                    <ForeName>Annalisa</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Cento</LastName>\n                    <ForeName>Valeria</ForeName>\n                    <Initials>V</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Residency in Microbiology and Virology, University of Milan, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Perno</LastName>\n                    <ForeName>Carlo Federico</ForeName>\n                    <Initials>CF</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Dept of Oncology and Oncohematology, University of Milan, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Andreoni</LastName>\n                    <ForeName>Massimo</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Infectious Diseases, University of &quot;Rome &quot;Tor Vergata&quot;. Rome, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <CollectiveName>Two-Drug Antiretroviral Regimens expert panel</CollectiveName>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>02</Month>\n                <Day>20</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Italy</Country>\n            <MedlineTA>New Microbiol</MedlineTA>\n            <NlmUniqueID>9516291</NlmUniqueID>\n            <ISSNLinking>1121-7138</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D044966">Anti-Retroviral Agents</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D044966" MajorTopicYN="Y">Anti-Retroviral Agents</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017408" MajorTopicYN="N">Guidelines as Topic</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015497" MajorTopicYN="Y">HIV-1</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Antiretroviral therapy</Keyword>\n            <Keyword MajorTopicYN="N">Dolutegravir</Keyword>\n            <Keyword MajorTopicYN="N">HIV</Keyword>\n            <Keyword MajorTopicYN="N">HIV drug-resistance</Keyword>\n            <Keyword MajorTopicYN="N">Two-drug regimens</Keyword>\n            <Keyword MajorTopicYN="N">Virological efficacy</Keyword>\n        </KeywordList>\n        <InvestigatorList>\n            <Investigator ValidYN="Y">\n                <LastName>Andreoni</LastName>\n                <ForeName>Massimo</ForeName>\n                <Initials>M</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Antinori</LastName>\n                <ForeName>Andrea</ForeName>\n                <Initials>A</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Ceccherini-Silberstein</LastName>\n                <ForeName>Francesca</ForeName>\n                <Initials>F</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Cento</LastName>\n                <ForeName>Valeria</ForeName>\n                <Initials>V</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Cossarizza</LastName>\n                <ForeName>Andrea</ForeName>\n                <Initials>A</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Clerici</LastName>\n                <ForeName>Mario</ForeName>\n                <Initials>M</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>D\'Arminio Monforte</LastName>\n                <ForeName>Antonella</ForeName>\n                <Initials>A</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>De Luca</LastName>\n                <ForeName>Andrea</ForeName>\n                <Initials>A</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Di Perri</LastName>\n                <ForeName>Giovanni</ForeName>\n                <Initials>G</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Galli</LastName>\n                <ForeName>Massimo</ForeName>\n                <Initials>M</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Gagliardini</LastName>\n                <ForeName>Roberta</ForeName>\n                <Initials>R</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Girardi</LastName>\n                <ForeName>Enrico</ForeName>\n                <Initials>E</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Gori</LastName>\n                <ForeName>Andrea</ForeName>\n                <Initials>A</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Lichtner</LastName>\n                <ForeName>Miriam</ForeName>\n                <Initials>M</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Lo Caputo</LastName>\n                <ForeName>Sergio</ForeName>\n                <Initials>S</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Madeddu</LastName>\n                <ForeName>Giordano</ForeName>\n                <Initials>G</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Maggiolo</LastName>\n                <ForeName>Franco</ForeName>\n                <Initials>F</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Marchetti</LastName>\n                <ForeName>Giulia</ForeName>\n                <Initials>G</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Mondi</LastName>\n                <ForeName>Annalisa</ForeName>\n                <Initials>A</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Mussini</LastName>\n                <ForeName>Cristina</ForeName>\n                <Initials>C</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Perno</LastName>\n                <ForeName>Carlo Federico</ForeName>\n                <Initials>CF</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Re</LastName>\n                <ForeName>Maria Carla</ForeName>\n                <Initials>MC</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Ripamonti</LastName>\n                <ForeName>Diego</ForeName>\n                <Initials>D</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Rizzardini</LastName>\n                <ForeName>Giuliano</ForeName>\n                <Initials>G</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Santoro</LastName>\n                <ForeName>Maria Mercedes</ForeName>\n                <Initials>MM</Initials>\n            </Investigator>\n            <Investigator ValidYN="Y">\n                <LastName>Zazzi</LastName>\n                <ForeName>Maurizio</ForeName>\n                <Initials>M</Initials>\n            </Investigator>\n        </InvestigatorList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>06</Month>\n                <Day>04</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>06</Month>\n                <Day>04</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>2</Month>\n                <Day>21</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>14</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>2</Month>\n                <Day>21</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30785209</ArticleId>\n            <ArticleId IdType="pii">496N083</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'